未经证实:2019年冠状病毒病(COVID-19)是一种由严重急性呼吸道综合症病毒引起的病毒性传染病,影响了全球数十亿人。呼吸道炎症的发病机制涉及白细胞介素-6浓度升高;因此,针对白细胞介素6受体的干预措施,如托珠单抗(TCZ),在COVID-19管理的困境中,已被视为潜在的治疗方法。该研究的目的是分析TCZ的疗效和安全性,并记录COVID-19患者的预后。
UNASSIGNED:在瓦多达拉的一家三级医院进行了每组80例患者(N=160)的回顾性病例对照研究,古吉拉特邦.将12岁以上非妊娠COVID-19阳性患者纳入研究,收集病史及相关资料后分为病例组(给予TCZ)和对照组(给予标准治疗)。从每个小组,进一步的数据以一般和系统检查的形式收集,炎症和序贯器官衰竭评估(SOFA)评分的调查和计算。
UNASSIGNED:病例组的总死亡率低于对照组。患有中度至重度疾病的患者,年龄<55岁,无合并症的患者和需氧量较高的患者在给予TCZ时死亡率较低.病例组炎症评分<3和SOFA评分<6与死亡率降低相关。此外,这项研究通过同时分析两个参数的组合发现了显著的结果,据我们所知,这在任何其他研究中都没有做过。
UNASSIGNED:与标准治疗相比,TCZ辅助治疗对总死亡率有益处,在疾病严重程度增加的患者中观察到特定的益处,年轻人到中年群体,没有合并症,更高的氧需求和更低的炎症和SOFA评分。
UNASSIGNED: Coronavirus disease 2019 (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome virus, which has affected billions of people across the globe. The pathogenesis of respiratory inflammation involves elevated concentration of interleukin-6; hence, interventions targeting interleukin-6 receptor, such as tocilizumab (TCZ), have been investigated as potential treatment amidst the dilemma of COVID-19 management. The aim of the study is to analyse the efficacy and safety of TCZ and record the outcome in COVID-19 patients.
UNASSIGNED: A retrospective
case-control study of 80 patients in each group (N = 160) was carried out in a tertiary care hospital in Vadodara, Gujarat. Non-pregnant COVID-19-positive patients above 12 years of age were included in the study and were divided into
case (those given TCZ) and control (those given standard treatment) groups after collecting their history and related data. From each group, further data was collected in the form of general and systemic examination, investigations and calculation of inflammatory and Sequential Organ Failure Assessment (SOFA) scores.
UNASSIGNED: Overall mortality was less in the
case group compared to the control group. Patients with moderate to severe disease, age <55 years, patients having no comorbidity and patients with higher oxygen demand had lower deaths when given TCZ. Inflammatory score <3 and SOFA score <6 were associated with reduced mortality in the
case group. Additionally, the study found significant results by simultaneously analysing two parameters in combination, which has not been done in any other study to the best of our knowledge.
UNASSIGNED: Adjuvant TCZ therapy had overall mortality benefit compared to standard treatment, with specific benefit observed in those with increasing disease severity, young to middle-age group, absence of comorbidity, higher oxygen requirements and lower inflammatory and SOFA scores.